INT144430

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.77
First Reported 2003
Last Reported 2010
Negated 8
Speculated 2
Reported most in Body
Documents 137
Total Number 140
Disease Relevance 103.87
Pain Relevance 8.66

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Erbb2) plasma membrane (Erbb2) nucleus (Erbb2)
kinase activity (Erbb2) cytoplasm (Erbb2)
Anatomy Link Frequency
lung 9
A549 5
BT-474 3
exocrine pancreas 2
MDA-MB-468 2
Erbb2 (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 94 100.00 Very High Very High Very High
Cannabinoid 1083 99.72 Very High Very High Very High
imagery 355 98.52 Very High Very High Very High
Inflammatory response 5 98.52 Very High Very High Very High
Central nervous system 527 97.40 Very High Very High Very High
cytokine 66 97.40 Very High Very High Very High
chemokine 20 96.88 Very High Very High Very High
agonist 296 96.16 Very High Very High Very High
positron emission tomography 173 95.36 Very High Very High Very High
metalloproteinase 127 94.44 High High
Disease Link Frequency Relevance Heat
Cancer 6824 100.00 Very High Very High Very High
Breast Cancer 2229 100.00 Very High Very High Very High
Lung Cancer 544 100.00 Very High Very High Very High
Advanced Or Metastatic Breast Cancer 460 99.98 Very High Very High Very High
Metastasis 1068 99.92 Very High Very High Very High
Carcinoma 273 99.90 Very High Very High Very High
Pancreatic Cancer 58 99.88 Very High Very High Very High
Targeted Disruption 80 99.86 Very High Very High Very High
Non-small-cell Lung Cancer 204 99.84 Very High Very High Very High
Noninfiltrating Intraductal Carcinoma 182 99.84 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Experimental evidence has shown that oestrogen-dependent MCF7 cells that over express HER2 are rendered tamoxifen resistant and have reduced numbers of ER [32,33].
Gene_expression (express) of HER2 in MCF7
1) Confidence 0.77 Published 2008 Journal Int Semin Surg Oncol Section Body Doc Link PMC2383915 Disease Relevance 0.48 Pain Relevance 0
Such results strongly suggest that over expression of HER2 predicts reduced response to adjuvant tamoxifen in patients with EBC, but does not exclude benefit in patients with HER2 and ER/PgR-positive tumours.
Gene_expression (expression) of HER2 associated with cancer
2) Confidence 0.77 Published 2008 Journal Int Semin Surg Oncol Section Body Doc Link PMC2383915 Disease Relevance 0.85 Pain Relevance 0
Two main methods exist for the determination of HER2 gene amplification and protein expression in breast cancer specimens, fluorescence in situ hybridisation or FISH (direct or indirect) and IHC.
Gene_expression (expression) of HER2 gene associated with breast cancer
3) Confidence 0.77 Published 2008 Journal Int Semin Surg Oncol Section Body Doc Link PMC2383915 Disease Relevance 1.10 Pain Relevance 0
None of the hyperplastic/dysplastic breast lesions overexpressed HER2.
Gene_expression (overexpressed) of HER2 associated with hyperplasia
4) Confidence 0.77 Published 2008 Journal Int Semin Surg Oncol Section Body Doc Link PMC2383915 Disease Relevance 1.63 Pain Relevance 0
Several authors have reported a higher frequency of HER2 over expression in ductal carcinoma in situ (DCIS) compared with invasive cancer [19,20] Similarly, Liu et al [20] have observed HER2 overexpression as determined by gene amplification using polymerase-chain reaction (PCR)-based techniques in 48% of in situ carcinomas compared with 21% of stage II invasive breast tumours.
Gene_expression (overexpression) of HER2 associated with cancer, breast cancer, carcinoma and noninfiltrating intraductal carcinoma
5) Confidence 0.77 Published 2008 Journal Int Semin Surg Oncol Section Body Doc Link PMC2383915 Disease Relevance 1.43 Pain Relevance 0
Many clinical studies have found an association between HER2 overexpression and Tamoxifen failure in metastatic breast cancer [42-45] and also a reduced response duration and survival duration in those treataed with adjuvant hormonal therapies.
Neg (failure) Gene_expression (overexpression) of HER2 associated with advanced or metastatic breast cancer
6) Confidence 0.77 Published 2008 Journal Int Semin Surg Oncol Section Body Doc Link PMC2383915 Disease Relevance 0.40 Pain Relevance 0.13
Recently a meta-analysis of seven studies[47] concluded that metastatic breast cancer overexpressing HER2 was very likely to be resistant to Tamoxifen (odds ratio of disease progression, 2.46).
Gene_expression (overexpressing) of HER2 associated with advanced or metastatic breast cancer and disease progression
7) Confidence 0.77 Published 2008 Journal Int Semin Surg Oncol Section Body Doc Link PMC2383915 Disease Relevance 0.65 Pain Relevance 0.12
Ridolfi et al (23) tested 750 consecutive invasive carcinomas for HER2 overexpression using both IHC and FISH techniques.
Gene_expression (overexpression) of HER2 associated with carcinoma
8) Confidence 0.77 Published 2008 Journal Int Semin Surg Oncol Section Body Doc Link PMC2383915 Disease Relevance 0.53 Pain Relevance 0
Hudziak et al, [59] showed that a MAB directed against the extracellular domain of p185 HER2 specifically inhibited the growth of breast tumour derived cells over expressing the HER2 gene product.
Gene_expression (expressing) of HER2 gene associated with breast cancer
9) Confidence 0.77 Published 2008 Journal Int Semin Surg Oncol Section Body Doc Link PMC2383915 Disease Relevance 0.79 Pain Relevance 0
They also showed that resistance to the cytotoxic effect of tumour necrosis factor alpha (a consequence of HER2 overexpression) was significantly reduced in the presence of the antibody.


Gene_expression (overexpression) of HER2 associated with necrosis and cancer
10) Confidence 0.77 Published 2008 Journal Int Semin Surg Oncol Section Body Doc Link PMC2383915 Disease Relevance 0.73 Pain Relevance 0
Although the trials are of relatively short followup duration, the treatment is associated with rare but significant side effects and the treatment is not without cost, Herceptin has undoubtedly made a real difference for those 25–30% of patients who overexpress the Her2/neu oncogene.
Gene_expression (overexpress) of Her2
11) Confidence 0.77 Published 2008 Journal Int Semin Surg Oncol Section Body Doc Link PMC2383915 Disease Relevance 0.40 Pain Relevance 0
It targets the external moiety of the Her2 receptor and prevents activation of the protein (possibly by preventing dimerisation) thereby preventing proliferation of breast cancer cells overexpressing Her2.


Gene_expression (overexpressing) of Her2 in external associated with breast cancer
12) Confidence 0.77 Published 2008 Journal Int Semin Surg Oncol Section Body Doc Link PMC2383915 Disease Relevance 0.71 Pain Relevance 0.04
The promoter of the HER-2 gene also contains an oestrogen response element which suppresses HER-2 expression on response to oestrogen and is overexpressed with tamoxifen [34,35].
Gene_expression (expression) of HER-2
13) Confidence 0.77 Published 2008 Journal Int Semin Surg Oncol Section Body Doc Link PMC2383915 Disease Relevance 0.43 Pain Relevance 0
HER2 expression also appears to show good concordance between the primary tumour and both synchronous and subsequent metastasis in both the intensity and pattern of IHC staining [22,23] suggesting that the oncogenic overexpression remains stable.


Gene_expression (expression) of HER2 associated with cancer and metastasis
14) Confidence 0.77 Published 2008 Journal Int Semin Surg Oncol Section Body Doc Link PMC2383915 Disease Relevance 1.56 Pain Relevance 0
Both experimental and clinical evidence have indicated that the HER2 pathway interacts with the ER pathway with retrospective clinical studies suggesting an inverse relationship between ER and HER-2 expression.
Gene_expression (expression) of HER-2
15) Confidence 0.77 Published 2008 Journal Int Semin Surg Oncol Section Body Doc Link PMC2383915 Disease Relevance 0.52 Pain Relevance 0
The GUN trial [46], revealed that HER-2 expression not only predicted tamoxifen resistance but also showed a worse outcome on tamoxifen compared to those who were untreated (possibly because of the heightened agonist action).
Gene_expression (expression) of HER-2 associated with agonist
16) Confidence 0.77 Published 2008 Journal Int Semin Surg Oncol Section Body Doc Link PMC2383915 Disease Relevance 0.53 Pain Relevance 0.13
In addition, 43 patients with metastatic disease and HER-2 overexpression in the primary tumor were treated with Trastuzumab.
Gene_expression (overexpression) of HER-2 associated with cancer and metastasis
17) Confidence 0.77 Published 2006 Journal Breast Cancer Res Section Body Doc Link PMC1779464 Disease Relevance 1.34 Pain Relevance 0.24
Along with 18F-labeled trastuzumab affibodies[29], 89Zr-DFO-trastuzumab represents one of the most promising radiotracers for non-invasive immunoPET measurements of HER2/neu expression in vivo.
Gene_expression (expression) of HER2/neu
18) Confidence 0.77 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2810330 Disease Relevance 0.21 Pain Relevance 0.04
The recovery of HER2/neu expression between 48 and 72 h is consistent with the increase in 89Zr-DFO-trastuzumab uptake observed in the biodistribution studies.


Gene_expression (expression) of HER2/neu
19) Confidence 0.77 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2810330 Disease Relevance 0.57 Pain Relevance 0
Trastuzumab and related mAb-fragments have been radiolabeled with a wide range of radionuclides and quantitative immunoPET imaging has been used to monitor the effect of administering Hsp90 inhibitors on HER2/neu expression levels.[19]–[30] Quantification of changes in HER2/neu expression in response to Hsp90 treatment has the potential to facilitate patient-specific dose regimes.
Gene_expression (expression) of HER2/neu associated with imagery
20) Confidence 0.77 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2810330 Disease Relevance 0.24 Pain Relevance 0.05

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox